Rigel Pharmaceuticals (RIGL) Revenue (QoQ) (2010 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.74% |
| Dec 31, 2025 | 0.49% |
| Sep 30, 2025 | -31.69% |
| Jun 30, 2025 | 90.66% |
| Mar 31, 2025 | -7.40% |
| Dec 31, 2024 | 4.14% |
| Sep 30, 2024 | 50.12% |
| Jun 30, 2024 | 24.74% |
| Mar 31, 2024 | -17.48% |
| Dec 31, 2023 | 27.22% |
| Sep 30, 2023 | 4.64% |
| Jun 30, 2023 | 3.13% |
| Mar 31, 2023 | -49.16% |
| Dec 31, 2022 | 128.82% |
| Sep 30, 2022 | -24.85% |
| Jun 30, 2022 | 78.18% |
| Mar 31, 2022 | -18.00% |
| Dec 31, 2021 | -5.26% |
| Sep 30, 2021 | -17.98% |
| Jun 30, 2021 | -67.58% |
| Mar 31, 2021 | 339.12% |
| Dec 31, 2020 | 0.33% |
| Sep 30, 2020 | 14.78% |
| Jun 30, 2020 | -71.27% |
| Mar 31, 2020 | 262.08% |
| Dec 31, 2019 | -26.16% |
| Sep 30, 2019 | 100.41% |
| Jun 30, 2019 | -17.56% |
| Mar 31, 2019 | -66.65% |
| Dec 31, 2018 | 678.15% |
| Sep 30, 2018 | 172.24% |
| Dec 31, 2017 | -598.22% |
| Mar 31, 2017 | 19.47% |
| Dec 31, 2016 | -20.21% |
| Sep 30, 2016 | -56.25% |
| Jun 30, 2016 | 70.89% |
| Mar 31, 2016 | -41.09% |
| Dec 31, 2015 | -34.31% |
| Sep 30, 2015 | 150.69% |
| Jun 30, 2015 | 138.02% |
| Jun 30, 2012 | 100.00% |
| Sep 30, 2011 | 1,002.53% |
| Sep 30, 2010 | 46.15% |